

# Anastasia Stukan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2729410/publications.pdf>

Version: 2024-02-01

12  
papers

9  
citations

2682572

2  
h-index

2550090

3  
g-index

12  
all docs

12  
docs citations

12  
times ranked

3  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dynamic changes in the tumor microenvironment under the effect of estradiol as a diagnostic tool and target for targeted cancer therapy. Bulletin of Siberian Medicine, 2022, 21, 171-182.	0.3	1
2	Evolution of the CDK4/6 inhibitor abemaciclib: from palliative to adjuvant therapy. Clinical experience with abemaciclib in patients with hormone-receptor-positive, HER2-negative breast cancer. Meditsinskiy Sovet, 2022, , 40-48.	0.5	0
3	Induction of ovarian steroidogenesis as an additional potential risk factor for progression in premenopausal patients with hormone-receptor-positive breast cancer receiving tamoxifen as adjuvant therapy. Meditsinskiy Sovet, 2022, , 131-138.	0.5	0
4	Mechanisms of metastasis and development of resistance to therapy in breast cancer. A clinical case of the effectiveness of ixabepilone in hormone-receptorpositive breast cancer with multidrug resistance. Meditsinskiy Sovet, 2021, , 138-146.	0.5	0
5	Liquid biopsy: the current state of the issue. Innovative Medicine of Kuban, 2021, , 57-63.	0.2	1
6	Germinal <i>BRCA</i>-mutation significance in the tumor microenvironment formation Efficacy of PARP inhibition in late-line therapy of metastatic castration-resistant prostate cancer. Onkourologiya, 2021, 17, 85-94.	0.3	2
7	Efficacy of the immune checkpoint inhibitor nivolumab in the treatment of advanced hepatocellular carcinoma with the exhausted possibilities of therapy with tyrosine kinase inhibitors. Meditsinskiy Sovet, 2021, , 84-93.	0.5	0
8	Molecular features evaluation of metastatic foci as the basis for metastatic breast cancer treatment personalization. Is there a place of CDK4/6-inhibitors in late-line therapy after chemotherapeutic regimens?. Meditsinskiy Sovet, 2021, , 54-61.	0.5	0
9	Role of pre-metastatic niche in organ specificity of breast cancer metastasis. Influence on metastatic potential as a basis for CDK4/6-inhibition efficacy in early therapy of disseminated hormone-receptor-positive disease. Meditsinskiy Sovet, 2021, , 25-34.	0.5	0
10	Clinical significance of P16-positive status and high index of proliferative activity in patients with oropharyngeal squamous cell carcinoma. Siberian Journal of Oncology, 2020, 19, 41-48.	0.3	1
11	PATHOGENETIC RATIONALE FOR THE USE OF CELL THERAPY IN LUNG INJURY ASSOCIATED WITH SARS-COV-2. Innovative Medicine of Kuban, 2020, , 69-78.	0.2	1
12	Human papillomavirus-associated oropharyngeal carcinoma: trends in epidemiology and methods for detecting the virus in tumors. Opuholi Golovy I Sei, 2018, 8, 77-83.	0.4	3